Interleukin-12 - Opportunities for the treatment of bladder cancer

被引：11

作者：

Clinton, SK

Canto, E

O'Donnell, MA

机构：

[1] Ohio State Univ, Arthur G James Canc Hosp, Div Hematol & Oncol, Columbus, OH 43210 USA

[2] Ohio State Univ, Richard J Solove Res Inst, Columbus, OH 43210 USA

[3] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA

[4] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Urol, Sch Med, Boston, MA 02115 USA

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 2000年 / 27卷 / 01期

关键词：

D O I：

10.1016/S0094-0143(05)70242-1

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Despite incomplete understanding of the human immune system, the rapid progress in tumor immunology provides a framework for effective and safe interventions in the near future. Early approaches in patients with cancer that have focused on the nonspecific and broad stimulation of the immune system by interferons and IL-12 will be replaced by the highly specific stimulation of immune reactions targeting precisely defined tumor antigens. IL-12 has several biologic properties that seem useful in immune therapy fur bladder cancer. The striking antitumor responses with IL-12 in preclinical animal models of bladder cancer provide optimism that future clinical trials involving this agent may impact on the risk and mortality associated with this disease.

引用

页码：147 / +

页数：10

共 78 条

[1]

Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency [J].